The overarching objective of the Massachusetts Alzheimer's Disease Research Center (MADRC) is to stimulate and support research of the highest quality in aging, Alzheimer's disease (AD), and related disorders. The specific goals are: To propose and support new research directed toward uncovering the etiology and pathogenetic mechanisms of AD and related dementias;to enhance collaborative research funded outside of the MADRC;and to catalyze education, training and information transfer related to dementia. Administrative, Clinical, Data and Statistical, Neuropathology, and Education Cores support 3 R01 style 5 year projects and 3 pilot projects/year. The Clinical Core has established a Longitudinal Cohort that follows ~600 individuals who are cognitively normal, have mild impairments, mild AD or other dementias. These subjects undergo full Uniform Data Set evaluations and data are submitted to NACC. Our retention rate to date (93% 1 year;97% 2 year) shows that these individuals are committed to participate in longitudinal studies. Over 60% of these individuals have already also contributed to at least one other research project related to aging and cognition, including 7 different neuroimaging studies and a major Biomarkers program. The Neuropathology Core has tissues on nearly 1400 subjects, and in the last 4 years supplied 3 dozen separate investigators with over 10,000 slides or specimens. The Data and Statistics Core has built a new state of the art data repository. The Education Core has continued its mission of outstanding community involvement, and has enhanced recruitment for MADRC programs. Three R01 style applications are closely linked to Core activities, and focus on the relationship between amyloid, clinical symptoms, and neurotoxicity: Two relate to longitudinal studies in MADRC subjects. The first asks what does positive PIB amyloid imaging mean in the setting of normal cognition? The second, led by a junior investigator, examines whether amyloid deposition in vessels (CAA) alters the course of dementia. The third project utilizes MADRC brain bank material to examine whether oligomeric forms of amyloid - in addition to, or instead of, fibrillar forms - are neurotoxic. The MADRC provides infrastructure to support local and national efforts in AD research: In the current grant period 44 investigators used MADRC resources to support 76 NIH funded projects;an additional 68 projects supported by non-Federal sources relied in part on MADRC for subjects or other resources. Going forward, the MADRC will continue to expand its clinical and neuropathological resources, its innovative training and scientific programs directed toward AD research.

Public Health Relevance

Alzheimer's disease is a devastating disorder of cognition causing dementia in millions of Americans. Our studies use clinical and laboratory tools to characterize the earliest phases of the disease, and to try to better understand the underlying causes of the brain damage that leads to dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-29
Application #
8235898
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Phelps, Creighton H
Project Start
1997-04-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
29
Fiscal Year
2012
Total Cost
$1,945,499
Indirect Cost
$479,944
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
DeVos, Sarah L; Corjuc, Bianca T; Commins, Caitlin et al. (2018) Tau reduction in the presence of amyloid-? prevents tau pathology and neuronal death in vivo. Brain 141:2194-2212
Lee, Christopher M; Jacobs, Heidi I L; Marquié, Marta et al. (2018) 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. J Alzheimers Dis 62:1691-1702
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Emerson, Sarah C; Waikar, Sushrut S; Fuentes, Claudio et al. (2018) Biomarker validation with an imperfect reference: Issues and bounds. Stat Methods Med Res 27:2933-2945
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Pasi, Marco; Marini, Sandro; Morotti, Andrea et al. (2018) Cerebellar Hematoma Location: Implications for the Underlying Microangiopathy. Stroke 49:207-210
Hopp, Sarah C; Lin, Yang; Oakley, Derek et al. (2018) The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. J Neuroinflammation 15:269

Showing the most recent 10 out of 966 publications